What is the 13F Pro Quality Score for MIRM?

13F Pro ranks Mirum Pharmaceuticals, Inc. (MIRM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MIRM's current score at https://13fpro.ai/research/MIRM (free sign-up required for the full ranking).

Where does 13F Pro source MIRM data?

All Mirum Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Mirum Pharmaceuticals, Inc. files with the SEC under CIK 1759425. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MIRM in?

Mirum Pharmaceuticals, Inc. (MIRM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MIRM research updated on 13F Pro?

MIRM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Mirum Pharmaceuticals, Inc.(MIRM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1759425 MIRM stock profile & AI dashboard →

13F Pro Quality Score

32.7/100

Rank #2,252 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

94.3/100

Profitability

6.0/100

Balance Sheet

0.9/100

Earnings Quality

30.0/100

Free Cash Flow

11.1/100

Institutional Flow

61.3/100

Revenue Scale

37.7/100

Dilution Risk

13.3/100

MIRM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Mirum Pharmaceuticals, Inc. (MIRM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MIRM at 32.7/100 on a 32-signal composite quality model, placing it at rank #2,252 of 2,879 stocks — the bottom half of the AI-ranked universe. MIRM scores in the top quartile across revenue growth (94.3). Areas of concern include balance sheet strength (0.9) and profitability (6.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 13.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Mirum Pharmaceuticals, Inc. reports quarterly revenue of $159.9M, net income of $-790.2M, free cash flow of $-229.4M. Top institutional holders of MIRM by reported 13-F value include Frazier Life Sciences Management, L.P., JANUS HENDERSON GROUP PLC, BlackRock,, based on the most recent SEC filings. MIRM trades on the Nasdaq exchange and files with the SEC under CIK 1759425. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MIRM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Mirum Pharmaceuticals, Inc. directly from SEC EDGAR. Mirum Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 8 and 89 since 2022, currently 32.7 — an improving long-term trajectory across 52 quarterly and live scoring snapshots.

✦

Fun facts about Mirum Pharmaceuticals, Inc.

Quirks, history, and lore behind MIRM — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap biopharmaceutical company listed on Nasdaq, headquartered in California, focused on developing drugs for rare liver diseases.
2
The Numbers
With revenue in the tens of millions and a lean commercial-stage operation, this company punches above its weight in a highly specialized niche most investors have never heard of.
3
The History
Founded around 2018, it quickly advanced a pipeline targeting cholestatic liver conditions — rare diseases where bile can't flow properly and patients have very few options.
4
The Secret
Its lead asset works by blocking a bile acid transporter in the gut, reducing the toxic buildup that causes debilitating itch and liver damage in children with rare genetic disorders.
5
The Lore
It scored an FDA approval for a drug targeting progressive familial intrahepatic cholestasis — a mouthful of a disease that affects only a handful of children per million births.
6
The Giveaway
Its approved drug Livmarli (maralixibat) gave kids with a devastating rare liver disease their first real shot at relief — and put this tiny pharma on the map with a ticker that sounds like a magic word.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$159.9M

Net Income

Q1 2026

$-790.2M

Free Cash Flow

Q1 2026

$-229.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+54.7% YoY

$521.3MFY 2025

FY22 $77.1MFY23 $186.4MFY24 $336.9MFY25 $521.3M

Net Income

+73.4% YoY

$-23.4MFY 2025

FY22 $-135.7MFY23 $-163.4MFY24 $-87.9MFY25 $-23.4M

Operating Income

+74.7% YoY

$-22.1MFY 2025

FY22 $-131.2MFY23 $-109.2MFY24 $-87.6MFY25 $-22.1M

EPS (Diluted)

+74.6% YoY

$-0.47FY 2025

FY22 $-4.02FY23 $-4.00FY24 $-1.85FY25 $-0.47

Total Assets

+25.7% YoY

$842.8MFY 2025

FY22 $352.9MFY23 $646.6MFY24 $670.8MFY25 $842.8M

Op. Cash Flow

+440.7% YoY

$55.8MFY 2025

FY22 $-120.1MFY23 $-70.9MFY24 $10.3MFY25 $55.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$521.3M +54.7%	$336.9M +80.8%	$186.4M +141.8%	$77.1M +302.7%	$19.1M	$0.00
Net Income	$-23.4M +73.4%	$-87.9M +46.2%	$-163.4M -20.5%	$-135.7M -61.5%	$-84.0M +18.7%	$-103.3M
Operating Income	$-22.1M +74.7%	$-87.6M +19.7%	$-109.2M +16.8%	$-131.2M +24.3%	$-173.4M -66.3%	$-104.3M
EPS (Diluted)	$-0.47 +74.6%	$-1.85 +53.8%	$-4.00 +0.5%	$-4.02 -45.1%	$-2.77	—
Total Assets	$842.8M +25.7%	$670.8M +3.7%	$646.6M +83.2%	$352.9M +19.8%	$294.7M +22.3%	$240.9M
Operating Cash Flow	$55.8M +440.7%	$10.3M +114.6%	$-70.9M +40.9%	$-120.1M +9.5%	$-132.8M -49.0%	$-89.1M

AI Insight: MIRM Financial Trends

Revenue growth stalled in Q1 2026 while company swung to massive $790M net loss, suggesting a significant one-time charge despite 12-quarter revenue uptrend.

• Revenue grew 105% from $78M in Q2 2024 to $160M in Q1 2026, demonstrating consistent quarterly expansion through Q4 2025.

• Operating cash flow turned sharply negative at -$229M in Q1 2026 versus +$40M in Q3 2025, reversing eight quarters of improvement.

• Net income swung from +$3M profit in Q3 2025 to -$790M loss in Q1 2026; operating loss of -$789M suggests non-cash charge or impairment.

⚠ Q1 2026 operating cash flow collapsed to -$229M despite positive operating income in prior quarter; assess sustainability and working capital drivers.

⚠ Equity declined from $315M in Q4 2025 to $242M in Q1 2026 amid massive loss; monitor balance sheet health and covenant compliance.

AI Insight: MIRM Ratio Trends

Mirum achieved profitability in Q3 2025 with positive operating margin of 2.0%, but slipped back to loss-making in Q4 2025 as TTM metrics deteriorated sharply.

• Operating margin swung from -13.6% in Q1 2025 to +2.0% in Q3 2025, marking first profitable quarter, before reverting to -3.1% in Q4 2025.

• TTM operating margin fell to -139.8% as of Q1 2026, reflecting accumulated losses dominating the trailing twelve-month period.

• ROE and ROA metrics improved sequentially from Q2 2025 (-9.2% and -3.2%) to Q3 2025 (4.0% and 1.5%), but deteriorated again in Q4 2025.

⚠ Q4 2025 loss-making reversal after Q3 profitability suggests seasonal or one-off headwind; sustainability of positive inflection unclear.

⚠ Q1 2026 data absent; TTM metrics severely negative, indicating near-term earnings pressure and cash-burn concerns.

Get alerted when MIRM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Mirum Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MIRM

Frazier Life Sciences Management, L.P.
$709.4M7,679,684 sh
JANUS HENDERSON GROUP PLC
$627.3M6,789,239 sh
BlackRock, Inc.
$355.3M3,846,530 sh
VANGUARD CAPITAL MANAGEMENT LLC
$223.1M2,414,776 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$209.4M70,000,000 sh
FMR LLC
$181.6M1,965,375 sh
STATE STREET CORP
$179.6M1,944,281 sh
BVF INC/IL
$146.4M1,584,727 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$132.3M1,432,083 sh
TENOR CAPITAL MANAGEMENT Co., L.P.
$131.7M43,792,000 sh

Fund	Value	Shares
Frazier Life Sciences Management, L.P.	$709.4M	7,679,684
JANUS HENDERSON GROUP PLC	$627.3M	6,789,239
BlackRock, Inc.	$355.3M	3,846,530
VANGUARD CAPITAL MANAGEMENT LLC	$223.1M	2,414,776
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$209.4M	70,000,000
FMR LLC	$181.6M	1,965,375
STATE STREET CORP	$179.6M	1,944,281
BVF INC/IL	$146.4M	1,584,727
VANGUARD PORTFOLIO MANAGEMENT LLC	$132.3M	1,432,083
TENOR CAPITAL MANAGEMENT Co., L.P.	$131.7M	43,792,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MIRM on your watchlist

Track score changes the day Mirum Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MIRM a good stock to buy?

13F Pro's AI-powered analysis of Mirum Pharmaceuticals, Inc. (MIRM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MIRM are available on the MIRM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MIRM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MIRM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Mirum Pharmaceuticals, Inc.'s investment landscape.